Edgewise Therapeutics (EWTX) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 143.4% versus a loss of 14.4%. Over five years, EWTX leads with a +120.2% price change compared with +9.3% for VRDN. Edgewise Therapeutics is the larger company by market cap ($4.24 billion vs $2.11 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | VRDN |
|---|---|---|
| Share price | $39.06 | $18.66 |
| Market cap | $4.24B | $2.11B |
| 1-day change | -0.43% | +1.74% |
| YTD return | +57.40% | -40.04% |
| 1-year return | +143.36% | -14.44% |
| 5-year return | +120.18% | +9.31% |
| EPS (TTM) | $-1.86 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $70.85M |
| Revenue growth (YoY) | — | +23359.93% |
| Net income (latest FY) | $-167.79M | $-342.60M |
| Operating margin | — | -512.91% |
| Net margin | — | -483.57% |
| 52-week high | $48.51 | $34.29 |
| 52-week low | $14.25 | $13.18 |
| Distance from 52-week high | -19.48% | -45.58% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.72% | +96.95% |
| Average volume | 1.34M | 1.71M |
| Shares outstanding | 108.60M | 113.29M |
| Employees | 127 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Edgewise Therapeutics is about 2.0 times larger than Viridian Therapeutics by market value ($4.24B vs $2.11B).
- EWTX has outperformed VRDN by 157.8 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 127 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
EWTX vs VRDN FAQ
Which is bigger, Edgewise Therapeutics or Viridian Therapeutics?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.24B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, EWTX or VRDN?
EWTX returned +143.36% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.